GLP-1 Agonists Show Promise for Psoriasis | Healio News
The potential of GLP-1 receptor agonists – medications initially developed for type 2 diabetes – is extending into dermatology, with emerging data suggesting benefits for conditions like psoriasis. Recent findings presented at Maui Derm 2026, as discussed by Dr. James Song, director of clinical research at Frontier Dermatology in Mill Creek, Washington, highlight a possible broader impact beyond simply clearing skin lesions.
Psoriasis is a chronic autoimmune disease that affects the skin, causing raised, red, scaly patches. It’s estimated to affect around 7.5 million adults in the United States, according to the National Psoriasis Foundation. Although treatments exist, ranging from topical creams to systemic medications, there’s ongoing research to identify new therapeutic avenues, particularly those that address the underlying inflammation driving the disease.
Beyond Skin Clearance: Exploring Additional Benefits
Dr. Song’s discussion at Maui Derm centered on the potential for GLP-1 receptor agonists to offer advantages beyond just reducing the visible symptoms of psoriasis. These medications perform by mimicking the effects of glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar levels. They’ve been shown to reduce cardiovascular events and mortality in individuals with psoriatic arthritis, as noted in a November 2025 report in Healio. This connection between metabolic health and inflammatory conditions like psoriasis is gaining increasing attention.
The precise mechanisms by which GLP-1 receptor agonists might impact psoriasis are still being investigated. However, researchers believe that GLP-1 receptors are present on immune cells involved in the inflammatory processes that drive psoriasis. By activating these receptors, the medications may help to modulate the immune response and reduce inflammation.
Understanding GLP-1 Receptor Agonists and Their Use
GLP-1 receptor agonists were originally designed to improve glycemic control in people with type 2 diabetes. They work by increasing insulin release, decreasing glucagon secretion, and slowing gastric emptying. Common examples of these medications include semaglutide (Ozempic, Rybelsus) and liraglutide (Victoza). While initially prescribed for diabetes, they’ve gained attention for their weight loss effects, leading to off-label use for this purpose. The potential for these medications to impact autoimmune conditions like psoriasis represents a new and exciting area of research.
It’s important to note that GLP-1 receptor agonists are not without potential side effects. Common side effects include nausea, vomiting, and diarrhea. More serious, though rare, side effects have similarly been reported. Individuals considering these medications should discuss the potential risks and benefits with their healthcare provider.
The Interplay of Inflammation and Metabolic Health
The emerging link between GLP-1 receptor agonists, psoriasis, and cardiovascular health underscores the complex interplay between inflammation and metabolic health. Psoriasis is associated with an increased risk of cardiovascular disease, and both conditions share common inflammatory pathways. Addressing these underlying inflammatory processes may offer a more holistic approach to managing these conditions.
The growing understanding of this connection is prompting researchers to explore whether GLP-1 receptor agonists could be used as part of a broader strategy to reduce cardiovascular risk in individuals with psoriasis. Further research is needed to determine the optimal role of these medications in this context.
Current Research and Future Directions
While the findings presented at Maui Derm are promising, Dr. Song emphasized the need for further research to fully understand the potential benefits of GLP-1 receptor agonists for psoriasis. Ongoing clinical trials are investigating the efficacy and safety of these medications in individuals with psoriasis, both as a standalone treatment and in combination with other therapies.
Researchers are also working to identify biomarkers that could help predict which individuals with psoriasis are most likely to respond to GLP-1 receptor agonists. This could allow for a more personalized approach to treatment, ensuring that the right patients receive the right therapy at the right time.
Disclosures and Conflicts of Interest
It’s important to acknowledge potential conflicts of interest when evaluating research findings. Dr. Song has financial relationships with numerous pharmaceutical companies involved in the development and marketing of psoriasis treatments, including AbbVie, Amgen, and Sanofi. He also holds editorial positions with the Journal of Psoriasis and Psoriatic Arthritis and serves on advisory boards for the International Psoriasis Council and the National Psoriasis Foundation. These relationships are disclosed to provide transparency and allow readers to assess potential biases.
What’s Next in Psoriasis Research?
The investigation into GLP-1 receptor agonists and psoriasis is part of a larger trend toward exploring novel therapeutic targets for autoimmune diseases. Researchers are increasingly focused on understanding the underlying immune mechanisms that drive these conditions and developing therapies that can selectively modulate the immune response. Expect to see continued research into the role of inflammation, metabolic health, and the gut microbiome in psoriasis and other autoimmune diseases. The National Institutes of Health (NIH) provides ongoing updates on research initiatives related to autoimmune diseases on their website.